- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Cetuximab and panitumumab for treating RAS wild-type colorectal cancer
Cetuximab and panitumumab for treating RAS wild-type colorectal cancer
Cancer
Gastrointestinal tract
12 July 2022
Published on 04 Jan 2022
Last Updated on 12 Jul 2022
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Cetuximab 100 mg/20 mL solution for infusion; and
Panitumumab 100 mg/5 mL concentrate for solution for infusion
as monotherapy or in combination with chemotherapy for treating RAS wild-type metastatic colorectal cancer.
Subsidy status
Panitumumab 100 mg/5 mL concentrate for solution for infusion is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication with effect from 4 January 2022.
Cetuximab 100 mg/20 mL solution for infusion is recommended for inclusion on the SDL for the abovementioned indication with effect from 1 September 2022.
PES Treatments for RAS wild type metastatic colorectal cancer (Updated 12 Jul 2022) [PDF, 119 KB]